BioVaxys Technology Corp. announces sale of TAET Software Co.
by CM Staff
BioVaxys says it has sold TAET Software Co. to 10402588 BC Ltd, a private company in B.C., in exchange for 500,000 shares of the Purchaser.
VANCOUVER — BioVaxys Technology Corp. announces that it has sold TAET Software Co. to 10402588 BC Ltd, a private company formed under the laws of British Columbia, in exchange for 500,000 shares of the Purchaser, with further potential future milestone payments totaling a maximum of 1,000,000 shares of the Purchaser and a maximum of USD$4,000,000 in cash.
James Passin, BioVaxys CEO, stated, “We are pleased to monetize our investment in TAET Software Corp.; exiting this medical software business will allow BioVaxys to refocus on its core business objectives of distributing OTC women’s healthcare products in the USA and advancing towards the launch of the planned Phase I trial for BVX-0918, our therapeutic ovarian cancer vaccine.”
BioVaxys Technology Corp. a biopharmaceuticals company based in Vacouver, Canada, is the exclusive US licensee and distributor of a portfolio of OTC female reproductive health products.
